CDK1 and carcinoma: In adenomas with early carcinomas, statistically significant results include TNXB with 7.7-fold downregulation (p ≤ 0.001), 4.4-fold upregulation of CDK1 (p ≤ 0.01), 14.1-fold upregulation of ANLN (p ≤ 0.001), and 26.3-fold upregulation of ECT2 (p ≤ 0.001).